Dr. Annaliesa S. Anderson is Senior Vice President and Chief Vaccines Officer at Pfizer. With over 30 years in pharmaceuticals, she leads global vaccine research, development, and medical affairs, advancing programs from early discovery through post-licensure—including candidates for C. difficile, Lyme disease, Group B Strep, and more. Dr. Anderson earned her PhD in biological sciences from the University of Warwick and has contributed to the development of numerous licensed vaccines, including for HPV at Merck and for pneumococcal disease, meningococcal disease, COVID-19, and RSV at Pfizer. During the SARS-CoV-2 pandemic, she co-led the development of an antiviral therapy for COVID-19. Dr. Anderson has co-authored over 170 peer-reviewed publications and book chapters and holds an extensive patent portfolio. In 2024, she was named among the Top 20 Women in Biopharma by Endpoints. She is a Fellow of the American Academy of Microbiology, the Infectious Diseases Society of America, the Academy of Medical Sciences, and the Royal Society of Medicine, and serves on multiple scientific and policy advisory boards.

Yvonne Hao joined Flagship Pioneering in 2025 as Chief Operating Officer and General Partner. In this role she leads key functional pillars that support Flagship and its ecosystem of companies, including HR and Talent, Legal and IP, IT/Digital, Communications, Government and Regulatory Affairs, and Facilities/Real Estate. Yvonne also contributes to strategic initiatives and serves on Flagship’s Resource Allocation Committee. In addition, she works alongside Flagship’s Growth Partners to help steward the firm’s later-stage companies, drawing on her experience in company building, operating, and investing.

Yvonne was most recently the Secretary of the Executive Office of Economic Development for the State of Massachusetts. Prior to her role in public service, Yvonne has had more than 25 years of experience as a senior executive, including as Co-founder, Managing Director and Advisor at investment firm Cove Hill Partners and as an Operating Partner at Pillar Ventures. Previously, she was the Chief Operating Officer and Chief Financial Officer of PillPack, where she led the company’s sale to Amazon in 2018. She is also a former Operating Partner at Bain Capital, where she held interim CEO and COO roles, served on boards, and worked closely with portfolio companies. Earlier in her career, she held senior leadership roles at Honeywell and McKinsey & Company.

Yvonne has been a Board Director of companies such as CarGurus, Flywire, Gentherm, ZipRecruiter, and Bose. She also has been involved in the community, and was the Vice Chair of the Board of Trustees of Beth Israel Lahey Health, and is a Trustee Emeriti of her alma mater, Williams College.

Yvonne earned a B.A. in economics and Asian studies from Williams College and an M.Phil. in Development/Economics from the University of Cambridge.

Faisal M. Khan, Ph.D. is the Corporate Vice President for Artificial Intelligence and Analytics at Novo Nordisk. His team focuses on the applications of AI and data science throughout the drug discovery and development lifecycle. His interests focus on the intersections of data science, digital health, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedical analytics, including diagnostics, devices, clinical trials/therapeutics, and payers/insurance. Dr. Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 100 published papers, abstracts, and patents on the applications of machine learning and artificial intelligence for healthcare and the life sciences.